Want to see EDIT full AI Analyst Report?

Editas Medicine (EDIT) Price & Analysis

3,589 Followers

EDIT Stock Chart & Stats

$3.28

$0.10(4.04%)

At close: Jul 27 4:00 PM EDT

$3.28

$0.10(4.04%)

Day’s Range― - ―

52-Week Range$1.66 - $4.54

Previous CloseN/A

Volume561.33K

Average Volume (3M)2.81M

Market Cap

$402.38M

Enterprise Value$246.12M

Total Cash (Recent Filing)$211.65M

Total Debt (Recent Filing)$15.51M

Price to Earnings (P/E)―

Beta2.55

Next Earnings

Nov 09, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.75

Shares Outstanding153,580,030

10 Day Avg. Volume2,476,937

30 Day Avg. Volume2,811,115

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)6.67

Price to Sales (P/S)4.49

P/FCF Ratio-1.10

Enterprise Value/Market Cap0.61

Enterprise Value/Revenue5.24

Enterprise Value/Gross Profit9.20

Enterprise Value/Ebitda-3.50

Forecast

1Y Price Target

$5.60

Price Target Upside70.73% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)-0.78

Revenue Forecast (FY)$25.89M

Bulls Say, Bears Say

Bulls Say

Improving Revenue And Gross MarginImproving revenue and positive gross profitability indicate a healthier mix or cost profile as Editas advances its pipeline. Although the company is not yet profitable, sustained top-line growth can improve operating leverage and provide a stronger base for future partnerships or commercialization.

Reduced LeverageThe substantial reduction in debt lowers balance-sheet risk and improves financial flexibility while Editas funds development programs. Lower leverage can reduce financing pressure, preserve strategic options, and make the company better positioned to manage continued volatility in clinical-stage biotechnology.

Strengthened Scientific GovernanceAdding an independent director with senior cardiovascular, academic, and Broad Institute experience strengthens scientific and clinical oversight. That expertise may improve governance around gene-editing programs, support strategic decisions, and enhance credibility with partners as development advances.

Bears Say

Persistent Net LossesDeep losses show that current revenue remains insufficient to cover research, development, and operating expenses. Until pipeline programs generate larger milestone, licensing, or product revenues, ongoing deficits can erode equity and limit the company’s ability to fund growth internally.

Structurally Negative Cash FlowHeavy cash consumption remains a central constraint despite moderation from prior periods. Continued negative operating and free cash flow means Editas must rely on existing reserves or external funding to sustain R&D, increasing financial dependence and making runway management strategically important.

Limited Commercial Revenue BaseThe absence of material marketed-product revenue leaves Editas dependent on collaboration payments, licensing income, milestones, and potential future royalties. This creates an uneven revenue base and makes financial progress contingent on development outcomes and successful partnering or commercialization.

Editas Medicine News

Editas slips amid pressure on gene-editing sector after Anthropic update

Editas Medicine (EDIT) is trading lower alongside other gene editing peers after Anthropic shared early findings on a...

13d ago

EDIT

Microsoft upgraded, HubSpot initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

14d ago

ALV

ARX

Editas Medicine upgraded to Buy at Guggenheim on EDIT-401 potential

As previously reported, Guggenheim upgraded Editas Medicine (EDIT) to Buy from Neutral with a $5 price target Should...

14d ago

EDIT

Editas Medicine upgraded to Buy from Neutral at Guggenheim

Guggenheim upgraded Editas Medicine (EDIT) to Buy from Neutral with a $5 price target Published first on TheFly...

14d ago

EDIT

Editas Medicine appoints Dan Ory as chief medical officer

Editas Medicine (EDIT) announced the appointment of Dan Ory as chief medical officer, effective immediately. Ory will oversee...

29d ago

EDIT

Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($EDIT) ), ( ($SGMT) ), ( ($DBX) ), ( ($ARCT)...

11d ago

DBX

PWR

Editas Medicine files $400M mixed securities shelf

16:27 EDT Editas Medicine (EDIT) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

1M ago

EDIT

Editas Medicine initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Editas Medicine (EDIT) with a Buy rating and $6 price target Published first on...

2M ago

EDIT

Phil Nadeau Reiterates Buy on Editas Medicine, Citing Strong Cash Runway and Upcoming EDIT-401 Clinical Catalyst

TD Cowen analyst Phil Nadeau has maintained their bullish stance on EDIT stock, giving a Buy rating yesterday....

2M ago

EDIT

Editas Medicine Strengthens Board With New Cardiology Director

An announcement from Editas Medicine ( ($EDIT) ) is now available. On August 3, 2026, Editas Medicine director...

2M ago

EDIT

Editas Medicine reports Q2 EPS (15c), consensus (28c)

Reports Q2 revenue $11.89M, consensus $2.75M. The revenue increase was primarily attributable to the recognition of deferred revenue...

2M ago

EDIT

EDIT Earnings this Week: How Will it Perform?

Editas Medicine Inc. (EDIT) is scheduled to report 2nd quarter earnings on 08/05/2026. Regarding Q2 estimates, Wall Street...

2M ago

EDIT

Editas Medicine Shareholders Back Board, Pay and Auditor

An announcement from Editas Medicine ( ($EDIT) ) is now available. At its June 17, 2026 annual meeting,...

4M ago

EDIT

Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO

Jeff Bezos’ new AI venture Prometheus has raised $12B in fresh funding, pushing its valuation to about $41B....

4M ago

EDIT FAQ

What was Editas Medicine Inc’s price range in the past 12 months?

Editas Medicine Inc lowest stock price was $1.66 and its highest was $4.54 in the past 12 months.

What is Editas Medicine Inc’s market cap?

Editas Medicine Inc’s market cap is $402.38M.

When is Editas Medicine Inc’s upcoming earnings report date?

Editas Medicine Inc’s upcoming earnings report date is Nov 09, 2026 which is in 33 days.

How were Editas Medicine Inc’s earnings last quarter?

Editas Medicine Inc released its earnings results on Aug 05, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.271 by $0.121.

Is Editas Medicine Inc overvalued?

According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Editas Medicine Inc pay dividends?

Editas Medicine Inc does not currently pay dividends.

What is Editas Medicine Inc’s EPS estimate?

Editas Medicine Inc’s EPS estimate is -0.19.

How many shares outstanding does Editas Medicine Inc have?

Editas Medicine Inc has 153,580,030 shares outstanding.

What happened to Editas Medicine Inc’s price movement after its last earnings report?

Editas Medicine Inc reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.271. Following the earnings report the stock price went up 5.455%.

Which hedge fund is a major shareholder of Editas Medicine Inc?

Currently, no hedge funds are holding shares in EDIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Editas Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

12.72%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine (EDIT) Earnings & Revenues

Historic Earnings Reports

EDIT Stock 12 Month Forecast

Average Price Target

$5.60

▲(70.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","9":"$9"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3,5,7,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.52,2.9415384615384617,3.3630769230769233,3.7846153846153845,4.206153846153846,4.627692307692308,5.049230769230769,5.470769230769231,5.892307692307693,6.313846153846154,6.735384615384616,7.156923076923077,7.578461538461539,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.52,2.756923076923077,2.993846153846154,3.230769230769231,3.4676923076923076,3.7046153846153844,3.941538461538461,4.178461538461539,4.415384615384616,4.6523076923076925,4.889230769230769,5.126153846153846,5.363076923076923,{"y":5.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.52,2.6338461538461537,2.747692307692308,2.8615384615384616,2.9753846153846153,3.0892307692307694,3.203076923076923,3.316923076923077,3.430769230769231,3.5446153846153847,3.6584615384615384,3.7723076923076926,3.8861538461538463,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >